Atlas Trials

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Clinical trial NCT07095127 · RECRUITING

Trial details

NCT number
NCT07095127
Sponsor
Nuvig Therapeutics, Inc.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Immune Thrombocytopenia (ITP)
Start date
2025-09-30
Primary completion
2027-06-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.